|1.||Steiner, Alexandre A: 2 articles (09/2014 - 06/2010)|
|2.||Yamazaki, Yoshinobu: 2 articles (05/2011 - 09/2002)|
|3.||Rasmussen, Helge H: 1 article (09/2015)|
|4.||Garcia, Alvaro: 1 article (09/2015)|
|5.||Hamilton, Elisha J: 1 article (09/2015)|
|6.||Liu, Chia-Chi: 1 article (09/2015)|
|7.||Fry, Natasha A: 1 article (09/2015)|
|8.||Karimi Galougahi, Keyvan: 1 article (09/2015)|
|9.||Figtree, Gemma A: 1 article (09/2015)|
|10.||Gavrilova, Oksana: 1 article (07/2015)|
07/19/1999 - "CL316243 is a highly selective and potent beta3-adrenergic receptor agonist, and has been shown in rodent models to be an effective agent for treating obesity and Type II diabetes. "
02/01/1997 - "CL316,243 may therefore be especially useful for the treatment of visceral fat type obesity related to various diseases."
07/01/2015 - "Anti-obesity and metabolic efficacy of the β3-adrenergic agonist, CL316243, in mice at thermoneutrality compared to 22°C."
05/01/2006 - "To obtain direct evidence for the role of UCP1 in the anti-obesity effect of beta3-adrenergic stimulation, in the present study, UCP1-KO and wild-type (WT) mice were fed on cafeteria diets for 8 wk and then given a beta3-adrenergic agonist, CL-316,243 (CL), or saline for 2 wk. A single injection of CL increased whole body oxygen consumption and brown fat temperature in WT mice but not in KO mice, and it elicited almost the same plasma free fatty acid response in WT and KO mice. "
07/01/1997 - "Objectives of the present study were to find out whether CL 316,243 could reverse established diet-induced obesity in rats and to identify the multilocular adipocytes that appeared in WAT. "
11/01/2000 - "Chronic administration of CL316243 to the A-ZIP/F-1 mice did not improve their thermogenesis, hyperglycemia, or hyperinsulinemia. "
09/01/2015 - "In vivo treatment with the β3-AR agonist CL316243 for 3 days eliminated the increase in indexes of oxidative stress, decreased coimmunoprecipitation of p22(phox) with p47(phox), abolished the hyperglycemia-induced increase in glutathionylation of eNOS and the Na(+)-K(+) pump β1-subunit, and abolished the decrease in pump current. "
07/01/1994 - "Furthermore, CL 316,243 decreased hyperglycemia and hypertriglyceridemia in MSG-treated mice. "
|3.||Abnormal Reflex (Hyperreflexia)
09/01/2001 - "Efficacy of the beta3-adrenergic receptor agonist CL-316243 on experimental bladder hyperreflexia and detrusor instability in the rat."
09/01/2002 - "These results indicate that in cerebral infarcted rats detrusor hyperreflexia can be suppressed by the selective beta3-adrenoceptor agonist CL316243 without increasing post-void residual volume and without significant cardiovascular side effects. "
09/01/2001 - "These data suggest that activating the beta3-adrenergic receptor in rat bladder using CL-316243 may directly inhibit smooth muscle contractility, experimental hyperreflexia and detrusor instability, and be useful for urge urinary incontinence."
|4.||Body Weight (Weight, Body)
04/01/1998 - "When a selective beta 3-adrenergic agonist, CL316,243 (0.1 mg/kg), was given orally to adult beagles every day for 5-7 weeks, body weight and girth were decreased compared with control placebo-treated dogs. "
01/01/2014 - "CL316243 (1 mg/kg) and OEA (5 mg/kg) co-administration over 6 days enhanced the reduction of both food intake and body weight gain, increased the energy expenditure and reduced the respiratory quotient (VCO2/VO2). "
06/01/1996 - "To examine whether long-term administration of a beta3-adrenoceptor agonist influences sympathetic nervous system (SNS) activity, norepinephrine (NE) turnover, a reliable indicator of SNS activity, in the interscapular brown adipose tissue (IBAT), the heart, and the spleen, as well as urinary excretion of NE, were measured using mice treated with CL316,243 (CL), a highly specific beta3-adrenoceptor agonist, at a dose that stimulated thermogenesis and reduced body weight. "
04/19/1996 - "Supplementation of a high fat diet with a beta 3-adrenergic receptor agonist (CL316,243) prevented obesity, but not hyperphagia associated with high fat feeding (body weights of high fat-fed A/J mice = 34.0 +/- 1.0 g; high fat plus CL316,243-fed mice = 26.8 +/- 0.5 g; n = 10). "
08/01/1997 - "These studies demonstrate that treatment with CL-316,243 improves basal and insulin-stimulated glucose disposal, and these effects occurred in the absence of a decrease in body weights and FFA concentrations. "
01/01/2000 - "The increase in left kidney weight seen after ureteral obstruction was suppressed by CL 316243. "
01/01/2000 - "After a complete ureteral obstruction produced by the inflation of a balloon catheter placed within the left lower ureter, the intraluminal ureteral pressure gradually rose to reach a plateau of approximately 52.5 mm Hg. Intravenous administration of isoproterenol (a nonselective beta-adrenoceptor agonist; 10 microg/kg) and CL 316243 (1 microg/kg) significantly decreased this elevated ureteral pressure (by 74.1 and 77.2%, respectively), with the reduction more sustained with CL 316243 than with isoproterenol. "
05/01/2011 - "To compare the potency and ureteral selectivity of the selective β(2)/β(3)-adrenoceptor agonist KUL-7211 with those of the nonselective β-adrenoceptor agonist isoproterenol, selective β(2)-adrenoceptor agonist terbutaline, and selective β(3)-adrenoceptor agonist CL-316243, we performed the study using an isolated porcine ureter and a porcine model of acute unilateral ureteral obstruction. "
05/01/2011 - "Ureteral selectivity of intravenous β-adrenoceptor agonists in pig model of acute ureteral obstruction: comparison of KUL-7211, a selective β2/β3 agonist, with isoproterenol, terbutaline, and CL-316243."
|1.||4- ethoxymethylene- 2- phenyl- 2- oxazoline- 5- one (phOx)
|7.||Adrenergic Agonists (Adrenergic Receptor Agonist)
|9.||Messenger RNA (mRNA)